South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, June 5, 2020
1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Matthew Stanley, DO	X
Dana Darger, RPh, Chair	X	Deidre Van Gilder, PharmD	X
Mikal Holland, MD	X	Mike Jockheck, DSS Staff	X
Bill Ladwig, RPh	X	Sarah Akers, DSS Staff	X
Kelley Oehlke, PharmD	X	Bill Snyder, DSS Staff	X
Lenny Petrik, PharmD	-		

Administrative Business

Darger called the meeting to order at 1:05 PM. The minutes of the December meeting were presented. Baack made a motion to approve. Ladwig seconded the motion. The motion was unanimously approved via roll call vote.

Synder updated the committee on the committee's hepatitis C recommendations. In addition, Synder provided an update on the appointments for the two committee vacancies.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from January 1, 2020 to March 31, 2020. A total of 1,770 PAs were reviewed of which 193 requests (11%) were received via telephone and 1,063 requests (60%) were received via fax, and 514 (29%) were reviewed via electronically. Darger requested more information regarding the duloxetine PAs.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from January 1, 2020 to March 31, 2020. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, amphetamines, anticonvulsants, and respiratory/CNS stimulants. The top 15 therapeutic classes make up 24.83% of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 12.65% of total claims. New utilization for Strensiq was noted on the top 50 drugs list based on amount paid. Ladwig inquired about the number of patients utilizing Epidiolex. Committee discussed hemophilia utilization and appropriate level of management. Darger contemplated whether it was appropriate to try methylphenidate or amphetamine first before allowing Vyvanse. Darger requested information on how other states are managing Vyvanse. Darger also discussed adding PA to Humira CF and Advair. Jockheck recommended adding these items to the next agenda.

New Committee Member

Darger, Jockheck, and committee members welcomed new committee member, Dr. Matthew Stanley. Stanley expressed his wish to add value to the committee.

Old Business

CGRP & Orilissa utilization

The committee reviewed the calcitonin gene related peptide (CGRP) utilization comparing 3Q19 through 1Q20. Utilization increased each quarter, including new utilization of Ubrelvy. Committee requested to review CGRP and triptan utilization concurrently. The committee also reviewed utilization of Orilissa comparing 4Q19 through 1Q20. Committee requested to continue reviewing utilization of both classes at the next meeting.

PA criteria review

- After reviewing Lyrica and pregabalin utilization, the committee discussed removing PA. Van Gilder made a motion to remove PA on Lyrica and pregabalin. Baack seconded the motion. The motion was unanimously approved via roll call vote.
- The committee discussed Lidoderm PA. Ladwig made a motion to remove PA on Lidoderm. Baack seconded the motion. The motion was unanimously approved via roll call vote.
- The committee reviewed utilization for all topical ketoconazoles. Ladwig commented on the appropriate utilization achieved from management.
- The committee reviewed the triptan utilization. After discussion, Van Gilder made a motion to remove PA on rizatriptan ODT. Ladwig seconded the motion. The motion was unanimously approved via roll call vote. Ladwig made a motion to add PA to Zomig spray requiring failure of oral triptan, then failure of sumatriptan spray. Baack seconded the motion. The motion was unanimously approved via roll call vote.
- The committee reviewed utilization for GLP-1 receptor agonists. Ladwig was satisfied with the utilization.

Opioid update

The committee reviewed 1Q20 opioid outcomes compared to previous quarters from the opioid initiatives. Effective 1Q20, opioid utilization includes Indian Health System (IHS) where previously it had been excluded. Therefore, utilization appears to have increased.

New Business

Compound summary

The committee reviewed the utilization for all compounds for year 2019. Committee was satisfied with the review.

Review of maintenance mediation 90-day dispense fee savings

Committee reviewed the maintenance medication 90-day dispensing fee estimated savings. Jockheck explained the estimated savings based on federal share and state funds. Ladwig expressed pharmacies using synchronized programs, the use of monthly adherence calls, and adherence concerns in the Medicaid population. Baack commented that some targeted medications may have improved compliance in rural areas especially in the time of COVID. Oehlke provided the VA experience with 90-day fills which improved compliance. After discussion, Baack made a motion to allow 3, 30-day consecutive fills for maintenance medications and then authorizing 90-day fills. Holland seconded the motion. The motion carried via roll call vote with one dissent from Ladwig.

Atypical antipsychotic utilization in children

Committee reviewed atypical antipsychotic utilization in children. Stanley commented the potential call to action for children on multiple products. Stanley and Baack conversed on titration; with Stanley

providing his experience on titration, delay in follow up appointments and slow titrations generally taking 90 days or more. An in-depth analysis was requested for the 235 members taking two or more products concurrently for more than 90 days (i.e., review PAs, prescriber specialty, dosage titration, age).

Review of Baqsimi & Gvoke
Baqsimi and Gvoke clinical information were presented for review. Stevan Tomich from Xeris provided public comment on Gvoke. Committee to monitor utilization.

Review of Ubrelvy and Reyvow
Ubrelvy and Reyvow clinical information were presented for review. Josh Bishop with Allergan provided public comment on Ubrelvy. Committee recommended adding Reyvow to the triptan PA. Committee recommended developing a PA for Ubrelvy. Baack made the motion for one step of all triptans before allowing Ubrelvy and patients with cardiovascular disease would be exempt from the step therapy. Oehlke seconded the motion. The motion was unanimously approved via a roll call vote.

Adjournment
The next meeting is scheduled for September 18, 2020. Baack made a motion to adjourn the meeting and Holland seconded the motion. The motion passed unanimously and the meeting adjourned at 3:00 PM.